With limited data on the real-world treatment of follicular lymphoma in a contemporary cohort of patients, researchers examined treatment patterns and outcomes among nearly 2,400 adult patients with an initial follicular lymphoma diagnosis between January 2011 and July 2020 who had received at least one line of therapy.

During a median follow-up of 43.1 months, the median time from diagnosis to first-line treatment was 38 days. Most patients (94.8%) received up to two lines of therapy, with the most common regimens across all lines of therapy being rituximab and bendamustine (52.7%); rituximab alone (34.1%); rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (20.3%); rituximab, cyclophosphamide, vincristine, and prednisone (7.2%), and Obinutuzumab and bendamustine (3.2%).

Use of newer first-line therapies was rare across all lines of therapy but more common in third-line therapy and beyond. Median times to next treatment after first-line and second-line onward therapies were 79.4 months and 38.3 months, respectively. Median overall survival after first-line and second-line onward therapies were not reached and 82.9 months, respectively.